Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration.

Metadatas

Authors
Discipline
type
Scope
Language
Identifiers
Source

Serveur académique Lausannois

Relations

This document is linked to :
info:eu-repo/semantics/altIdentifier/doi/10.1136/bjophthalmol-2018-312318

This document is linked to :
info:eu-repo/semantics/altIdentifier/pmid/30030393

This document is linked to :
info:eu-repo/semantics/altIdentifier/eissn/1468-2079

This document is linked to :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_A0255087CC949

Collection

Serveur Académique Lausannois

Organization

Université de Lausanne et CHUV

Licenses

info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/

Keywords 0

Aged; Angiogenesis Inhibitors/administration & dosage; Antidepressive Agents/therapeutic use; Depression/complications; Depression/diagnostic imaging; Drug Therapy, Combination; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Intravitreal Injections; Male; Prospective Studies; Ranibizumab/administration & dosage; Receptors, Vascular Endothelial Growth Factor/administration & dosage; Recombinant Fusion Proteins/administration & dosage; Retina/diagnostic imaging; Retreatment/methods; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A/antagonists & inhibitors; Wet Macular Degeneration/complications; Wet Macular Degeneration/diagnosis; Wet Macular Degeneration/drug therapy; angiogenesis; degeneration; drugs; medical treatment; retina

Similar subjects En

Therapy Factors Agents, Manufacturers' Manufacturers' representatives Factors

Cite this document

I. Mantel et al., « Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration. », Serveur académique Lausannois, ID : 10.1136/bjophthalmol-2018-312318

Metrics

Share / Export

Abstract 0

Vascular endothelial growth factor (VEGF) is a key player in the pathogenesis of neovascular age-related macular degeneration (nAMD) and is also involved in the final common pathway of antidepressant medication. This study investigated the relationship between the need for anti-VEGF retreatment in patients with nAMD and antidepressant medication, and the potential impact of ocular structural factors. Data from two identical prospective 2-year treatment protocols using ranibizumab or aflibercept in a variable-dosing regimen ('Observe-and-Plan') were analysed. Retreatment requirement was compared with antidepressant medication intake (primary outcome) and a variety of ocular factors from baseline and from month 3 response (secondary outcomes), using univariate and multivariate analyses. Of the 206 included patients (227 eyes), 19 were on antidepressant medication. Their nAMD eyes significantly more often had pigment epithelium detachment (PED, p=0.04). Multivariate analysis revealed a significant association between anti-VEGF retreatment requirement and antidepressant medication use (p=0.027), as well as thicker central retinal thickness at month 3 (p

document thumbnail

From the same authors

On the same subjects

Within the same disciplines